Amneal Makes Second US Biosimilar Launch With Filgrastim
Releuko Version Of Neupogen Follows Alymsys Bevacizumab Rival To Avastin
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.
You may also be interested in...
Apobiologix’s new Lapelga autoinjector that the firm has just introduced in Canada is only the second on-body pegfilgrastim device to launch after Amgen’s Neulasta original.
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.